Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Keytruda showed modest benefits for people with hepatocellular carcinoma, and combining Opdivo with Yervoy improved outcomes.
Seventy percent of liver cancer patients had either a partial response or stable disease.
A third of patients taking neoadjuvant Opdivo had complete responses in an early analysis.
Half of people with worse liver function responded well to immunotherapy.
A second immunotherapy option is now available for hepatocellular carcinoma.
Engineered T cells prevent recurrence over five years.
Immunotherapy had a low response rate, but most responders continue to do well.
The median survival exceeded 15 months for patients previously treated with the only approved first-line therapy.
Opdivo will be used to treat hepatocellular carcinoma, which can be caused by hepatitis B or C.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.